Seamless Therapeutics
Business Services · Germany · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Tatzberg 47/49, Dresden, Saxony, 01307, ...Phone Number
+49 35121246900Website
www.seamlesstx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Seamless Therapeutics
Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. The company's technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. The company is applying the company's proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.Explore more
Seamless Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Seamless Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Seamless Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Seamless Therapeutics
Check if Seamless Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Seamless Therapeutics launches new products
Check out if Seamless Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Seamless Therapeutics has new funding data
Earning: See what the market has to say on Seamless Therapeutics recently announced quarterly report
Seamless Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Seamless Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Seamless Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Seamless Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Seamless Therapeutics.
Seamless Therapeutics financials insights
Gather financial insights about Seamless Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Angel/Seed
$12.5M
Seamless Therapeutics Tech Stack
A closer look at the technologies used by Seamless Therapeutics
Most Recent Scoops
Facilities Relocation / Expansion
Seamless Therapeutics is planning to move offices in January 2026. The move will impact approximately 12 employees at the existing office located at 10 Maguire Rd Bldg 2, Suite #100, Lexington, MA.
Facilities Relocation/Expansion
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Seamless Therapeutics News & Media
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership
Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss
Seamless Therapeutics announces research collaboration and licensing agreement with Eli Lilly for gene therapy for genetic hearing disordersSeamless Therapeutics Expands Board of Directors with Appointment of Alvin Shih
Dresden, Germany, and Lexington, MA, May 8, 2025 – Seamless Therapeutics, today announced the appointment of Alvin Shih, M.D., M.B.A., as an Independent Director to its Board. Dr. Shih is an experienced drug developer and physician with a track record of successfully building and guiding companies focused on multiple therapeutic areas, including rare diseases. Dr Shih’s appointment to our Board will further strengthen the company as it advances its unique pipeline of programmable recombinase proSeamless Therapeutics to Present New Data at ESGCT Demonstrating its Ability to Reprogram Large Serine Recombinases to Specific Target Sites in the Human Genome
DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)--Seamless Therapeutics today announced that it will be presenting new preclinical data, including human cell data, highlighting its unique platform’s capabilities to reprogram large serine recombinases (LSRs) to target naturally occurring loci in the human genome. The company’s recombinases are engineered to precisely excise, exchange, invert, or insert gene-sized DNA fragments in any target gene sequence, independent of the cell’s natural DN
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Seamless Therapeutics
Sign Up For FreeTo access detailed company insights
Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. The company's technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. The company is applying the company's proprietary know-how t... Read More
